Vasileios K Kavouridis1,2, Alessandro Boaro1,2, Jeffrey Dorr2,3, Elise Y Cho1,2, J Bryan Iorgulescu1,2,4,5, David A Reardon2,4,6, Omar Arnaout1,2,6, Timothy R Smith1,2,6. 1. 1Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital. 2. 2Harvard Medical School. 3. 3Department of Radiology, Brigham and Women's Hospital. 4. 4Department of Medical Oncology, Dana-Farber Cancer Institute. 5. 5Department of Pathology, Brigham and Women's Hospital; and. 6. 6Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
OBJECTIVE: While the effect of increased extent of resection (EOR) on survival in diffuse infiltrating low-grade glioma (LGG) patients is well established, there is still uncertainty about the influence of the new WHO molecular subtypes. The authors designed a retrospective analysis to assess the interplay between EOR and molecular classes. METHODS: The authors retrospectively reviewed the records of 326 patients treated surgically for hemispheric WHO grade II LGG at Brigham and Women's Hospital and Massachusetts General Hospital (2000-2017). EOR was calculated volumetrically and Cox proportional hazards models were built to assess for predictive factors of overall survival (OS), progression-free survival (PFS), and malignant progression-free survival (MPFS). RESULTS: There were 43 deaths (13.2%; median follow-up 5.4 years) among 326 LGG patients. Median preoperative tumor volume was 31.2 cm3 (IQR 12.9-66.0), and median postoperative residual tumor volume was 5.8 cm3 (IQR 1.1-20.5). On multivariable Cox regression, increasing postoperative volume was associated with worse OS (HR 1.02 per cm3; 95% CI 1.00-1.03; p = 0.016), PFS (HR 1.01 per cm3; 95% CI 1.00-1.02; p = 0.001), and MPFS (HR 1.01 per cm3; 95% CI 1.00-1.02; p = 0.035). This result was more pronounced in the worse prognosis subtypes of IDH-mutant and IDH-wildtype astrocytoma, for which differences in survival manifested in cases with residual tumor volume of only 1 cm3. In oligodendroglioma patients, postoperative residuals impacted survival when exceeding 8 cm3. Other significant predictors of OS were age at diagnosis, IDH-mutant and IDH-wildtype astrocytoma classes, adjuvant radiotherapy, and increasing preoperative volume. CONCLUSIONS: The results corroborate the role of EOR in survival and malignant transformation across all molecular subtypes of diffuse LGG. IDH-mutant and IDH-wildtype astrocytomas are affected even by minimal postoperative residuals and patients could potentially benefit from a more aggressive surgical approach.
OBJECTIVE: While the effect of increased extent of resection (EOR) on survival in diffuse infiltrating low-grade glioma (LGG) patients is well established, there is still uncertainty about the influence of the new WHO molecular subtypes. The authors designed a retrospective analysis to assess the interplay between EOR and molecular classes. METHODS: The authors retrospectively reviewed the records of 326 patients treated surgically for hemispheric WHO grade II LGG at Brigham and Women's Hospital and Massachusetts General Hospital (2000-2017). EOR was calculated volumetrically and Cox proportional hazards models were built to assess for predictive factors of overall survival (OS), progression-free survival (PFS), and malignant progression-free survival (MPFS). RESULTS: There were 43 deaths (13.2%; median follow-up 5.4 years) among 326 LGG patients. Median preoperative tumor volume was 31.2 cm3 (IQR 12.9-66.0), and median postoperative residual tumor volume was 5.8 cm3 (IQR 1.1-20.5). On multivariable Cox regression, increasing postoperative volume was associated with worse OS (HR 1.02 per cm3; 95% CI 1.00-1.03; p = 0.016), PFS (HR 1.01 per cm3; 95% CI 1.00-1.02; p = 0.001), and MPFS (HR 1.01 per cm3; 95% CI 1.00-1.02; p = 0.035). This result was more pronounced in the worse prognosis subtypes of IDH-mutant and IDH-wildtype astrocytoma, for which differences in survival manifested in cases with residual tumor volume of only 1 cm3. In oligodendrogliomapatients, postoperative residuals impacted survival when exceeding 8 cm3. Other significant predictors of OS were age at diagnosis, IDH-mutant and IDH-wildtype astrocytoma classes, adjuvant radiotherapy, and increasing preoperative volume. CONCLUSIONS: The results corroborate the role of EOR in survival and malignant transformation across all molecular subtypes of diffuse LGG. IDH-mutant and IDH-wildtype astrocytomas are affected even by minimal postoperative residuals and patients could potentially benefit from a more aggressive surgical approach.
Authors: Elizabeth B Claus; Andres Horlacher; Liangge Hsu; Richard B Schwartz; Donna Dello-Iacono; Florian Talos; Ferenc A Jolesz; Peter M Black Journal: Cancer Date: 2005-03-15 Impact factor: 6.860
Authors: L Mariani; P Siegenthaler; R Guzman; D Friedrich; A R Fathi; C Ozdoba; J Weis; P Ballinari; R W Seiler Journal: Acta Neurochir (Wien) Date: 2004-03-22 Impact factor: 2.216
Authors: Maarten M J Wijnenga; Pim J French; Hendrikus J Dubbink; Winand N M Dinjens; Peggy N Atmodimedjo; Johan M Kros; Marion Smits; Renske Gahrmann; Geert-Jan Rutten; Jeroen B Verheul; Ruth Fleischeuer; Clemens M F Dirven; Arnaud J P E Vincent; Martin J van den Bent Journal: Neuro Oncol Date: 2018-01-10 Impact factor: 12.300
Authors: Justin S Smith; Edward F Chang; Kathleen R Lamborn; Susan M Chang; Michael D Prados; Soonmee Cha; Tarik Tihan; Scott Vandenberg; Michael W McDermott; Mitchel S Berger Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: A S Jakola; A J Skjulsvik; K S Myrmel; K Sjåvik; G Unsgård; S H Torp; K Aaberg; T Berg; H Y Dai; K Johnsen; R Kloster; O Solheim Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Stefanie Bette; Johannes Kaesmacher; Thomas Huber; Claire Delbridge; Florian Ringel; Tobias Boeckh-Behrens; Bernhard Meyer; Claus Zimmer; Jan S Kirschke; Jens Gempt Journal: World Neurosurg Date: 2016-03-19 Impact factor: 2.210
Authors: Maya Harary; Vasileios K Kavouridis; Matthew Torre; Hasan A Zaidi; Ugonma N Chukwueke; David A Reardon; Timothy R Smith; J Bryan Iorgulescu Journal: Neuro Oncol Date: 2020-03-05 Impact factor: 12.300
Authors: Louise Carstam; Alba Corell; Anja Smits; Anna Dénes; Hanna Barchéus; Klara Modin; Helene Sjögren; Sandra Ferreyra Vega; Thomas Olsson Bontell; Helena Carén; Asgeir Store Jakola Journal: Front Oncol Date: 2022-01-10 Impact factor: 6.244
Authors: Bodil Karoline Ravn Munkvold; Ole Solheim; Jiri Bartek; Alba Corell; Eddie de Dios; Sasha Gulati; Eirik Helseth; Klas Holmgren; Margret Jensdottir; Mina Lundborg; Eduardo Erasmo Mendoza Mireles; Ruby Mahesparan; Øystein Vesterli Tveiten; Peter Milos; Henrietta Nittby Redebrandt; Lars Kjelsberg Pedersen; Jon Ramm-Pettersen; Rickard L Sjöberg; Björn Sjögren; Kristin Sjåvik; Anja Smits; Gregor Tomasevic; Tomás Gómez Vecchio; Einar O Vik-Mo; Maria Zetterling; Øyvind Salvesen; Asgeir S Jakola Journal: Neurooncol Pract Date: 2021-09-04